Prognostic Factors in Children with HLH Investigated
|
By LabMedica International staff writers Posted on 27 Oct 2016 |

Image: A photomicrograph of a bone marrow showing stromal macrophages containing numerous red blood cells in their cytoplasm from a patient with hemophagocytic lymphohistiocytosis (Photo courtesy of Nephron).
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease characterized by a rapidly fatal hematological disorder usually associated with malignancies and severe infections and it presents with prolonged high fever that could not be controlled by antibiotics.
Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. Early diagnosis and combined treatment can effectively control this life-threatening disease.
Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).
The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.
Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.
The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.
Related Links:
Guangdong Medical College
Other manifestations of HLH are hepatosplenomegaly, cytopenia, widespread infiltration with lymphocytes, and benign-looking histiocytes with hemophagocytosis in the bone marrow, liver, spleen, or lymph nodes. Early diagnosis and combined treatment can effectively control this life-threatening disease.
Scientists at the Guangdong Medical College (Shenzhen, People’s Republic of China) carried out a retrospective analysis on HLH from January 1, 2000, to November 30, 2013. Of the 56 pediatric patients, 35 were boys and 21 were girls with a median age of 4.5 years (range: four months to 12 years) at the onset of HLH. The median duration before diagnosis of HLH was 1.5 weeks (range: one week to six weeks). The most common clinical symptoms observed were fever (100%), hepatomegaly or splenomegaly (95.24%), and pancytopenia (100%).
The team found that characteristic laboratory values presented with increased ferritin (64.29%), triglycerides (78.6%), transaminases (81%), bilirubin (67.5%), lactate dehydrogenase (95.2%), and decreased fibrinogen (61.9%), sodium (40.5%), and potassium (30.9%). Bone marrow aspiration showed hemophagocytosis in 48 cases (85.7%). Among the clinical and laboratory features analyzed, high lactate dehydrogenase (LDH) of greater than 2,000 U/L, high bilirubin of greater than 2 mg/mL, and younger age less than 2 years old at the time of diagnosis indicated worst outcome.
Anemia was observed in 39 patients (five cases with hemoglobin level less than 90 g/L, 27 cases less than 60–89 g/L, seven cases less than 30–59 g/L), neutropenia (neutrophil count less than 1.5×109/L) in 28 patients (22 cases less than 0.5–1.0×109/L, and five cases less than 0.5×109/L, and thrombocytopenia (platelet count less than 100×109/L) in 35 patients (33 cases with platelet count less than 20–99×109/L and two cases with platelet count less than 20×109/L). Examination of bone marrow aspiration showed hemophagocytosis in 48 (85.7%) patients.
The authors concluded that the etiology of HLH is complicated and early diagnosis is difficult. The level of LDH and bilirubin may predict the severity of HLH and depending on the clinical presentation, individualized therapy is needed for different patients. The study was published on October 11, 2016, in the Journal of Blood Medicine.
Related Links:
Guangdong Medical College
Latest Hematology News
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more
Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
Respiratory viruses such as influenza A/B and SARS‑CoV‑2 continue to burden urgent care and emergency settings, where rapid, reliable differentiation guides therapy and infection control.... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







